The greatest challenge to medicine is to bring to the bedside the latest developments in contemporary science. This challenge can only be met by developing a cadre of investigators who can conduct high quality research that is geared to strengthen patient-oriented investigations. Hence, this training grant proposal seeks support to prepare individuals (MD, MD/PhD, or PhD) for a career in biomedical science as it relates to Rheumatology. The program is based in a large Division of Rheumatology with 30 faculty members including 14 federally funded investigators and active clinical and basic research programs. The Division of Rheumatology, including its related clinics, is part of the David Geffen School of Medicine at UCLA with its clinical and biomedical science departments. The primary faculty advisors come not only from divisions within the Department of Medicine but also from the Departments of Pathology, Microbiol/lmmunol /Mol. Genetics, Pharmacology, and School of Public Health. The broad areas of expertise covered include autoimmunity, basic immunology, clinical intervention and therapeutics, genomics, gene expression and therapy, and health quality, economics and policy. The program is well supported by core facilities as well as by academic courses and a campus-wide translational immunology program initiated by the PI. It is believed that this Rheumatology program provides unique resources and will continue to enlarge the pool of individuals with a career interest in research as it relates to the subspecialty, a pool that is far too small to meet the requirements of the next decades as molecular medicine is increasingly applied in the clinic. The first year of the fellowship program consists of extensive clinical training and is funded through local sources. During the 2nd and 3rd years, the trainee will work in his/her chosen area of research, while maintaining sufficient clinical activity to fulfill the specialty board requirements. The trainees desiring and/or requiring experience to make the transition to academic investigator will be funded through the proposed T32 and for those who elect PhD or Master's curricula, through the UCLA STAR (Specialty Training in Advanced Research) program. This application seeks support for the critical 2-year period which transitions the trainee from her/his initial clinical rheumatology experience to a career in academic rheumatology. The application also seeks two-year training support for non-clinical postdoctoral trainees who desire to train in Rheumatology to develop an academic research career in the subspecialty.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Institutional National Research Service Award (T32)
Project #
5T32AR053463-03
Application #
7628470
Study Section
Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee (AMS)
Program Officer
Mancini, Marie
Project Start
2007-06-01
Project End
2012-05-31
Budget Start
2009-06-01
Budget End
2010-05-31
Support Year
3
Fiscal Year
2009
Total Cost
$202,236
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Kafaja, Suzanne; Valera, Isela; Divekar, Anagha A et al. (2018) pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis. JCI Insight 3:
Khanna, Dinesh; Hays, Ron D; Shreiner, Andrew B et al. (2017) Responsiveness to Change and Minimally Important Differences of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptoms Scales. Dig Dis Sci 62:1186-1192
Lee, A D; Spiegel, B M; Hays, R D et al. (2017) Gastrointestinal symptom severity in irritable bowel syndrome, inflammatory bowel disease and the general population. Neurogastroenterol Motil 29:
Epeldegui, Marta; Blom, Bianca; Uittenbogaart, Christel H (2015) BST2/Tetherin is constitutively expressed on human thymocytes with the phenotype and function of Treg cells. Eur J Immunol 45:728-37
King, Jennifer K; Philips, Rachael L; Eriksson, Anna U et al. (2015) Langerhans Cells Maintain Local Tissue Tolerance in a Model of Systemic Autoimmune Disease. J Immunol 195:464-76
Spiegel, Brennan M R; Hays, Ron D; Bolus, Roger et al. (2014) Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales. Am J Gastroenterol 109:1804-14
Cohen, Erica; Bolus, Roger; Khanna, Dinesh et al. (2014) GERD symptoms in the general population: prevalence and severity versus care-seeking patients. Dig Dis Sci 59:2488-96
Wong, Maida; La Cava, Antonio; Hahn, Bevra H (2013) Blockade of programmed death-1 in young (New Zealand Black x New Zealand White)F1 mice promotes the suppressive capacity of CD4+ regulatory T cells protecting from lupus-like disease. J Immunol 190:5402-10
Khanna, Dinesh; Maranian, Paul; Rothrock, Nan et al. (2012) Feasibility and construct validity of PROMIS and ""legacy"" instruments in an academic scleroderma clinic. Value Health 15:128-34
Khanna, Puja P; Perez-Ruiz, Fernando; Maranian, Paul et al. (2011) Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. Rheumatology (Oxford) 50:740-5

Showing the most recent 10 out of 30 publications